Literature DB >> 35003891

Dimeric FAPI with potential for tumor theranostics.

Chunxia Qin1,2, Yangmeihui Song1,2, Weibo Cai3, Xiaoli Lan1,2.   

Abstract

Radionuclide-labeled fibroblast activation protein inhibitors (FAPIs) are popular nuclear imaging probes in recent years. It's of great significance for tumor diagnosis and has great potential in tumor treatment. However, optimization of the probes is needed to further increase tumor uptake and prolong tumor retention for improved treatment efficacy and fewer side effects. In this issue of AJNMMI, Moon et al. reported two squaramide coupled FAPI conjugates (DOTA.(SA.FAPi)2 and DOTAGA.(SA.FAPi)2) and labeled them with 68Ga. The resulted tracers showed increased tumor accumulation and persistent retention, which led to an advance in PET imaging. The use of dimeric structures provides a feasible strategy to develop radiotherapeutic analogs of FAP inhibitors. AJNMMI
Copyright © 2021.

Entities:  

Keywords:  Dimer; endoradiotherapy; fibroblast activation protein inhibitor (FAPI); imaging; tumor

Year:  2021        PMID: 35003891      PMCID: PMC8727879     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  25 in total

1.  Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy.

Authors:  Thomas Lindner; Annette Altmann; Susanne Krämer; Christian Kleist; Anastasia Loktev; Clemens Kratochwil; Frederik Giesel; Walter Mier; Frederik Marme; Jürgen Debus; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

2.  68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Deep K Hathi; Ella F Jones
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

Review 3.  Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool.

Authors:  Punit Sharma; Shashank Shekhar Singh; Shankaramurthy Gayana
Journal:  Clin Nucl Med       Date:  2021-03-01       Impact factor: 7.794

4.  Synthesis and Preliminary Evaluation of 131I-Labeled FAPI Tracers for Cancer Theranostics.

Authors:  Huan Ma; Feize Li; Guohua Shen; Huawei Cai; Weihao Liu; Tu Lan; Yuanyou Yang; Jijun Yang; Jiali Liao; Ning Liu
Journal:  Mol Pharm       Date:  2021-09-30       Impact factor: 4.939

5.  Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer.

Authors:  Liang Zhao; Bo Niu; Jianyang Fang; Yizhen Pang; Siyang Li; Chengrong Xie; Long Sun; Xianzhong Zhang; Zhide Guo; Qin Lin; Haojun Chen
Journal:  J Nucl Med       Date:  2021-09-23       Impact factor: 11.082

6.  Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.

Authors:  Mengxin Xu; Pu Zhang; Jie Ding; Junyi Chen; Li Huo; Zhibo Liu
Journal:  J Nucl Med       Date:  2021-09-30       Impact factor: 11.082

7.  Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor.

Authors:  Johannes Toms; Jürgen Kogler; Simone Maschauer; Christoph Daniel; Christian Schmidkonz; Torsten Kuwert; Olaf Prante
Journal:  J Nucl Med       Date:  2020-04-24       Impact factor: 10.057

8.  A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.

Authors:  Sanjana Ballal; Madhav Prasad Yadav; Vasko Kramer; Euy Sung Moon; Frank Roesch; Madhav Tripathi; Soumyaranjan Mallick; Sreedharan Thankarajan ArunRaj; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-11       Impact factor: 9.236

9.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.

Authors:  Catherine Meyer; Magnus Dahlbom; Thomas Lindner; Sebastien Vauclin; Christine Mona; Roger Slavik; Johannes Czernin; Uwe Haberkorn; Jeremie Calais
Journal:  J Nucl Med       Date:  2019-12-13       Impact factor: 10.057

10.  Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.

Authors:  Richard P Baum; Christiane Schuchardt; Aviral Singh; Maythinee Chantadisai; Franz C Robiller; Jingjing Zhang; Dirk Mueller; Alexander Eismant; Frankis Almaguel; Dirk Zboralski; Frank Osterkamp; Aileen Hoehne; Ulrich Reineke; Christiane Smerling; Harshad R Kulkarni
Journal:  J Nucl Med       Date:  2021-06-24       Impact factor: 10.057

View more
  1 in total

1.  Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond.

Authors:  Muhsin H Younis; Sara Malih; Xiaoli Lan; Mohammad Javad Rasaee; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05       Impact factor: 10.057

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.